Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

For details of the enhanced Pregnancy Prevention Programme please click on the prescribing information links below.
Prescribing Information
Herceptin® (trastuzumab) IV 150 mg UK
Perjeta® (pertuzumab) UK
Herceptin® (trastuzumab) SC 600 mg UK
Phesgo SC®▼ (pertuzumab-trastuzumab) UK

Best practice video for preparing PHESGO ®▼(pertuzumab-trastuzumab) for subcutaneous (SC) administration

 

This video is intended for healthcare professionals from Great Britain and Northern Ireland. It has been developed by Roche Products Limited to be used as guidance only. In the first instance if you have any questions relating to the handling of PHESGO, please refer to the summary of product characteristics. If you need any further information then please refer to the ‘safety data sheet'1 for PHESGO which is based on the handling of PHESGO in industrial processes. Always follow your local institution’s risk assessments and guidelines, and handle PHESGO in accordance with your institution’s hygiene and safety practices.

 

 

Ryan Crockford, Clinical Nurse Specialist (CNS) based at the Sussex Cancer Centre Chemotherapy Unit demonstrates best practice on how PHESGO should be stored and then drawn up in preparation for subcutaneous injection into a patient.

This report is intended to be viewed online in your web browser. Should you require additional information regarding the content of the video or on any other Roche products please click here to contact us

 

Sign in or register

To learn more about Roche products or meetings and congresses, please sign in or click here to register.

Access information, news and resources about our medicines and the therapy areas in which they are used.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd.
Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
For biological medicines, adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.